Detalhe da pesquisa
1.
A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease.
Clin Infect Dis
; 76(3): e1186-e1194, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35925555
2.
Direct evidence gap on fixed versus adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: Systematic review and individual patient data meta-analysis.
Trop Med Int Health
; 28(1): 2-16, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36420767
3.
Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial.
Lancet Infect Dis
; 24(4): 395-403, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38218194
4.
The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform.
PLoS Negl Trop Dis
; 15(8): e0009697, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34398888
5.
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.
Lancet Infect Dis
; 21(8): 1129-1140, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33836161
6.
Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis.
PLoS Negl Trop Dis
; 14(8): e0008529, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32804966
7.
Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America.
Expert Rev Anti Infect Ther
; 17(3): 145-157, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30712412
8.
Benznidazole in Chagas disease study: do the data justify progression to phase 3? - Authors' reply.
Lancet Infect Dis
; 21(8): 1067, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34331879
9.
Response to `letter to the editor: 'Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America'´.
Expert Rev Anti Infect Ther
; 17(9): 673-675, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31361163